Literature DB >> 11709545

Familial and sporadic forms of central core disease are associated with mutations in the C-terminal domain of the skeletal muscle ryanodine receptor.

N Monnier1, N B Romero, J Lerale, P Landrieu, Y Nivoche, M Fardeau, J Lunardi.   

Abstract

Central core disease (CCD) is an autosomal dominant congenital myopathy. Diagnosis is based on the presence of cores in skeletal muscles. CCD has been linked to the gene encoding the ryanodine receptor (RYR1) and is considered to be an allelic disease of malignant hyperthermia susceptibility. However, the report of a recessive form of transmission together with a variable clinical presentation has raised the question of the genetic heterogeneity of the disease. Analyzing a panel of 34 families exclusively recruited on the basis of both clinically and morphologically expressed CCD, 12 different mutations of the C-terminal domain of RYR1 have been identified in 16 unrelated families. Morphological analysis of the patients' muscles showed different aspects of cores, all of them associated with mutations in the C-terminal region of RYR1. Furthermore, we characterized the presence of neomutations in the RyR1 gene in four families. This indicates that neomutations into the RyR1 gene are not a rare event and must be taken into account for genetic studies of families that present with congenital myopathies type 'central core disease'. Three mutations led to the deletion in frame of amino acids. This is the first report of amino acid deletions in RYR1 associated with CCD. According to a four-transmembrane domain model, the mutations concentrated mostly in the myoplasmic and luminal loops linking, respectively, transmembrane domains T1 and T2 or T3 and T4 of RYR1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11709545     DOI: 10.1093/hmg/10.22.2581

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  31 in total

1.  Clinical utility gene card for: Central core disease.

Authors:  Suzanne Lillis; Stephen Abbs; Clemens R Mueller; Francesco Muntoni; Heinz Jungbluth
Journal:  Eur J Hum Genet       Date:  2011-10-12       Impact factor: 4.246

2.  Functional properties of ryanodine receptors carrying three amino acid substitutions identified in patients affected by multi-minicore disease and central core disease, expressed in immortalized lymphocytes.

Authors:  Sylvie Ducreux; Francesco Zorzato; Ana Ferreiro; Heinz Jungbluth; Francesco Muntoni; Nicole Monnier; Clemens R Müller; Susan Treves
Journal:  Biochem J       Date:  2006-04-15       Impact factor: 3.857

3.  Basal bioenergetic abnormalities in skeletal muscle from ryanodine receptor malignant hyperthermia-susceptible R163C knock-in mice.

Authors:  Cecilia Giulivi; Catherine Ross-Inta; Alicja Omanska-Klusek; Eleonora Napoli; Danielle Sakaguchi; Genaro Barrientos; Paul D Allen; Isaac N Pessah
Journal:  J Biol Chem       Date:  2010-10-26       Impact factor: 5.157

4.  Single channel properties of heterotetrameric mutant RyR1 ion channels linked to core myopathies.

Authors:  Le Xu; Ying Wang; Naohiro Yamaguchi; Daniel A Pasek; Gerhard Meissner
Journal:  J Biol Chem       Date:  2008-01-01       Impact factor: 5.157

5.  [Hotline for malignant hyperthermia. New telephone number for the German nationwide 24 h service center: 08221/9600].

Authors:  W Klingler; F Lehmann-Horn; U Schulte-Sasse
Journal:  Anaesthesist       Date:  2011-02       Impact factor: 1.041

6.  RYR1 and CACNA1S genetic variants identified with statin-associated muscle symptoms.

Authors:  Paul J Isackson; Jianxin Wang; Mohammad Zia; Paul Spurgeon; Adrian Levesque; Jonathan Bard; Smitha James; Norma Nowak; Tae Keun Lee; Georgirene D Vladutiu
Journal:  Pharmacogenomics       Date:  2018-10-16       Impact factor: 2.533

7.  Exon skipping as a therapeutic strategy applied to an RYR1 mutation with pseudo-exon inclusion causing a severe core myopathy.

Authors:  John Rendu; Julie Brocard; Eric Denarier; Nicole Monnier; France Piétri-Rouxel; Cyriaque Beley; Nathalie Roux-Buisson; Brigitte Gilbert-Dussardier; Marie José Perez; Norma Romero; Luis Garcia; Joël Lunardi; Julien Fauré; Anne Fourest-Lieuvin; Isabelle Marty
Journal:  Hum Gene Ther       Date:  2013-07       Impact factor: 5.695

8.  RYR1 mutations as a cause of ophthalmoplegia, facial weakness, and malignant hyperthermia.

Authors:  Sherin Shaaban; Leigh Ramos-Platt; Floyd H Gilles; Wai-Man Chan; Caroline Andrews; Umberto De Girolami; Joseph Demer; Elizabeth C Engle
Journal:  JAMA Ophthalmol       Date:  2013-12       Impact factor: 7.389

9.  Central core disease: clinical, pathological, and genetic features.

Authors:  R M Quinlivan; C R Muller; M Davis; N G Laing; G A Evans; J Dwyer; J Dove; A P Roberts; C A Sewry
Journal:  Arch Dis Child       Date:  2003-12       Impact factor: 3.791

10.  Novel Homozygous Missense Mutation in RYR1 Leads to Severe Congenital Ptosis, Ophthalmoplegia, and Scoliosis in the Absence of Myopathy.

Authors:  Nafi Dilaver; Neda Mazaheri; Reza Maroofian; Jawaher Zeighami; Tahere Seifi; Mina Zamani; Alireza Sedaghat; Gholam Reza Shariati; Hamid Galehdari
Journal:  Mol Syndromol       Date:  2017-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.